Browsing Tag
obesity
46 posts
Torrent Pharma (NSE: TORNTPHARM) enters GLP-1 market with Sembolic and Semalix as over 40 rivals chase semaglutide patent expiry windfall
Torrent Pharmaceuticals launches India's first generic oral semaglutide alongside injectable Sembolic as GLP-1 patent expires. What the pricing and strategy mean. Read more.
Structure Therapeutics (Nasdaq: GPCR) posts 16% weight loss with oral GLP-1 drug aleniglipron, setting up Phase 3 push
Structure Therapeutics' aleniglipron hits 16% weight loss at 44 weeks in Phase 2, matching injectables. Read the full analysis before Phase 3 begins.
Why MetaVia’s patent move may matter more than early weight loss data in the obesity market
MetaVia Inc. secures patent protection for its dual incretin obesity drug DA-1726 through 2041. Find out why this matters for investors and competitors.
Ascletis Pharma advances ASC36 into clinical development, betting on oral amylin peptides for obesity
Ascletis Pharma Inc. moves ASC36 into clinical development, signalling a strategic push into oral amylin peptides for obesity. Find out what this means next.
Mazdutide phase 1b results from Innovent Biologics offer new hope for adolescent obesity in China
Find out how Innovent Biologics’ mazdutide trial could change adolescent obesity treatment in China—phase 3 launch is next.
Can Ascletis’ obesity pipeline redefine oral and monthly peptide therapy in 2026?
Find out how Ascletis’ oral and monthly obesity therapies are challenging industry norms with next-gen peptide technology.
Mangoceuticals lands breakthrough partnership with Eli Lilly and Novo Nordisk to deliver low-cost GLP-1 care
Find out how Mangoceuticals’ partnership with Eli Lilly and Novo Nordisk could transform affordable access to Zepbound and Wegovy obesity treatments.
Neumora (NASDAQ: NMRA) to begin Phase 1 trial of oral NLRP3 obesity pill in early 2026: Can it rival GLP-1 pills?
Find out how Neumora Therapeutics’ oral obesity candidate NMRA‑215 is advancing to human trials. Could it reshape the future of weight loss therapies?
Ventyx Biosciences announces positive Phase 2 trial data for VTX3232 in obesity and cardiometabolic risk
Find out how Ventyx Biosciences’ VTX3232 is reshaping the obesity and cardiometabolic space through inflammation-targeted innovation.
Novo Nordisk stock rises on Wegovy STEER data: Can semaglutide cement its lead over Eli Lilly?
Novo Nordisk shares gained after STEER study showed Wegovy cut heart risks by 57% over tirzepatide. Find out why semaglutide may lead the GLP-1 race.